

3<sup>rd</sup> Meeting

# European Myeloma Network Meeting



Virtual | April 6-9, 2022

## FACULTY

|                        |                     |                                     |
|------------------------|---------------------|-------------------------------------|
| Hervé Meral            | Avet-Loiseau        | Toulouse, France                    |
| Mario Niccolò          | Beksac              | Ankara, Turkey                      |
| Annemiek Michele       | Boccadoro           | Turin, Italy                        |
| Gordon Thomas          | Bolli               | Milan, Italy                        |
| Mattia Michel          | Broijl              | Rotterdam, The Netherlands          |
| Meletios A. Isabelle   | Cavo                | Bologna, Italy                      |
| Brian G.M. Hermann     | Cook                | Leeds, United Kingdom               |
| Thierry Carlos         | Cupedo              | Rotterdam, The Netherlands          |
| Jaime Francesca        | D'Agostino          | Turin, Italy                        |
| Hartmut Roman          | Delforge            | Leuven, Belgium                     |
| Jean-Luc Graham        | Dimopoulos          | Athens, Greece                      |
| Martin Efstathios      | Durand-Zaleski      | Paris, France                       |
| Shaji Marc             | Durie               | North Hollywood, USA                |
| Xavier Heinz           | Einsele             | Würzburg, Germany                   |
| Salomon Maria-Victoria | Facon               | Lille, France                       |
| Roberto                | Fernández de Larrea | Barcelona, Spain                    |
|                        | Gallego             | Navarra, Spain                      |
|                        | Gay                 | Turin, Italy                        |
|                        | Goldschmidt         | Heidelberg, Germany                 |
|                        | Hajek               | Ostrava, Czech Republic             |
|                        | Harousseau          | Nantes, France                      |
|                        | Jackson             | Newcastle upon Tyne, United Kingdom |
|                        | Kaiser              | London, United Kingdom              |
|                        | Kastritis           | Athens, Greece                      |
|                        | Kumar               | Rochester, USA                      |
|                        | Labetoulle          | Paris, France                       |
|                        | Leleu               | Poitiers, France                    |
|                        | Ludwig              | Wien, Austria                       |
|                        | Manier              | Lille, France                       |
|                        | Mateos              | Salamanca, Spain                    |
|                        | Mina                | Turin, Italy                        |

|                                |                     |                            |
|--------------------------------|---------------------|----------------------------|
| Monique C. Philippe            | Minnema             | Utrecht, The Netherlands   |
| Kate Nikhil C.                 | Moreau              | Nantes, France             |
| Enrique M. Stefania            | Morgan              | Edinburgh, United Kingdom  |
| Bruno Giovanni                 | Munshi              | Boston, USA                |
| Charlotte Noemi                | Ocio                | Santander, Spain           |
| Marc Jakub                     | Oliva               | Turin, Italy               |
| Noopur Karthik                 | Paiva               | Pamplona, Spain            |
| Leo Paula                      | Palladini           | Pavia, Italy               |
| Jesus Hans                     | Pawlyn              | London, United Kingdom     |
| Fredrik Hellem                 | Puig                | Salamanca, Spain           |
| Tobias Schmidt                 | Raab                | Heidelberg, Germany        |
| Pieter Evangelos               | Radocha             | Hradec Kralove, Czechia    |
| Cyrille Carin                  | Raje                | Boston, USA                |
| Niels Marie                    | Ramasamy            | Oxford, United Kingdom     |
| Josephine M.I. Katja Christina | Rasche              | Würzburg, Germany          |
| Kwee Elena                     | Rodriguez Otero     | Pamplona, Spagna           |
| Sonja                          | San-Miguel          | Navarra, Spain             |
|                                | Scheurer            | Brussels, Belgium          |
|                                | Schjesvold          | Oslo, Norway               |
|                                | Slørdahl            | Trondheim, Norway          |
|                                | Sonneveld           | Rotterdam, The Netherlands |
|                                | Terpos              | Athens, Greece             |
|                                | Touzeau             | Nantes, France             |
|                                | Uyl                 | Rotterdam, The Netherlands |
|                                | van de Donk         | Amsterdam, The Netherlands |
|                                | Von Lilienfeld-Toal | Jena, Germany              |
|                                | Vos                 | Amsterdam, The Netherlands |
|                                | Weisel              | Hamburg, Germany           |
|                                | Yong                | London, United Kingdom     |
|                                | Zamagni             | Bologna, Italy             |
|                                | Zweegman            | Amsterdam, The Netherlands |

## WEDNESDAY, APRIL 6, 2022

14.00-14.15 **OPENING CEREMONY**

14.15-14.45 **SESSION I: CLINICAL STUDIES IN PROGRESS**

*Chairpersons: H. Goldschmidt, T.S. Slørdahl*

New studies under the EMN - **F. Gay**

National studies and collaborative trials in Europe - **C. Touzeau**

New studies in the USA - **S. Kumar**

15.00-15.30 **SESSION II: PATIENT PERSPECTIVE: PATIENT ASSOCIATION TALK**

*Chairpersons: B.G.M. Durie, H. Scheurer*

MPE and patients in Europe - **H. Scheurer**

IMF and patients in the USA - **B.G.M. Durie**

15.45-16.30 **SESSION III: EMN-EHA joint session: Access to new treatments**

*Chairpersons: I. Durand-Zaleski, H. Ludwig*

Treatment access problems in the evolving treatment landscape:  
the clinician's view - **J.L. Harousseau**

The Atlas initiative and how to improve access for patients - **K. Morgan**

Health economics & cost-effectiveness: how should drugs be paid for? - **C. Uyl**  
Discussion

16.45-18.05 **SESSION IV: BEST ABSTRACTS - ORAL PRESENTATIONS**

*Chairpersons: A. Broijl, F.H. Schjesvold*

**B01**

STROMAL CELL-NEUTROPHIL INTERACTIONS PROMOTE A PRO-TUMOR ENVIRONMENT  
IN MULTIPLE MYELOMA

M. de Jong, C. Fokkema, T. van Heusden, N. Papazian, S. Tahri, Z. Kellermayer, P. Vermeulen,  
M. van Duin, P. van de Woestijne, A. Broijl, P. Sonneveld, T. Cupedo (*Rotterdam-NL*)

**B02**

REVERTING THE TUMOR-STROMAL METABOLIC COUPLING BY TARGETING LIPIDS RAFTS  
DYNAMICS TO INCREASE SENSITIVITY TO BELANTAMAB MAFODITIN IN MULTIPLE MYELOMA  
A. Romano, E. La Spina, D. Tibullo, C. Giallongo, G. Scandura, A. Barbato, F. Di Raimondo (*Catania-IT*)

**B03**

SKELETAL-RELATED EVENTS AND ABNORMAL MRI PATTERN AT DIAGNOSIS ARE ASSOCIATED  
WITH INFERIOR OVERALL SURVIVAL IN PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA  
E. Terpos, M. Gavriatopoulou, I. Ntanasis-Stathopoulos, A. Briasoulis, S. Gumeni, P. Malandrakis,  
E-D. Papanagnou, M. Migkou, N. Kanellias, E. Kastritis, I. P. Trougakos, M. A. Dimopoulos (*Athens-GR*)

**B04**

COMBINATION OF SUBCUTANEOUS TECLISTAMAB WITH DARATUMUMAB IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM): RESULTS FROM A PHASE 1B MULTICOHORT STUDY

P. Rodriguez-Otero, B. Dholaria, E. Askari, D. Reece, N. van de Donk, A. Chari, H. Goldschmidt, A. Krishnan, T. Martin, M. Mateos, D. Morillo, C. Rodriguez, L. Rosinol, J. San-Miguel, A. Balari, R. Wäsch, K. Weisel, R. Verona, S. Lin, T. Prior, M. Wade, B. Weiss, J. Goldberg, A. Oriol, P. Hari (Navarra-ES, Nashville-USA, Madrid-ES, Toronto-CA, Amsterdam-NL, New York-USA, Heidelberg-DE, Duarte-USA, San Francisco-USA, Salamanca-ES, Winston-Salem-USA, Barcelona-ES, Freiburg-DE, Hamburg-DE, Spring House-USA, Raritan-USA, Milwaukee-USA)

**B05**

RESULTS FROM A META-ANALYSIS OF CILTACABTAGENE AUTOLEUCEL COMPARED TO PHYSICIAN'S CHOICE OF TREATMENT IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA

F. Gay, J.G. Berdeja, V. De Stefano, P. Hari, B. Hooper, A. Haltner, S. Kumar, T. Martin, M.V. Mateos, P. Moreau, E. Rosta, I.A. Samjoo, S.Z. Usmani, K. Weisel, C.C. Jackson, Y. Olyslager, J.M. Schechter, M. Vogel, A. Garrett, S. Lee, T. Nesheiwat, L. Pacaud, C. Zhou, S. Valluri, L.J. Costa, Y. Lin (Torino, Nashville-USA, Roma, Milwaukee-USA, Sydney-CA, Rochester -USA), San Francisco-USA, Salamanca-ES, Nantes-FR, Burlington-CA, Charlotte-USA, Hamburg-DE, Raritan-USA, Beerse-BE, Piscataway-USA, Birmingham-USA)

**B06**

SUBCUTANEOUS TALQUETAMAB IN COMBINATION WITH DARATUMUMAB IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM): PHASE 1B RESULTS

M. Mateos, P. Hari, N. Bahlis, A. Chari, N.W.C.J. van de Donk, B. Dholaria, A.L. Garfall, H. Goldschmidt, K.M. Kortüm, A. Krishnan, T. Martin, D. Morillo, A. Oriol, D. Reece, C. Rodriguez, P. Rodríguez-Otero, J.F. San-Miguel, S.Z. Usmani, R. Verona, S.X.W. Lin, T.J. Prior, M. Wade, B. Weiss, J.D. Goldberg, E. Askari (Salamanca-ES, Milwaukee-USA, Calgary-CA, New York-USA, Amsterdam-NL, Nashville-USA, Philadelphia-USA, Heidelberg-DE, Würzburg-DE, Duarte-USA, San Francisco-USA, Madrid-ES, Badalona-ES, Toronto-CA, Winston-Salem-USA, Navarra-ES, Charlotte-USA, Spring House-USA, Raritan-USA)

**B07**

SAFETY AND EFFICACY OF CILTACABTAGENE AUTOLEUCEL, A CHIMERIC ANTIGEN RECEPTOR T-CELL THERAPY DIRECTED AGAINST B-CELL MATURATION ANTIGEN IN PATIENTS WITH MULTIPLE MYELOMA AND EARLY RELAPSE AFTER INITIAL THERAPY: CARTITUDE-2 RESULTS

N.W.C.J. van de Donk, M. Delforge, M. Agha, A.D. Cohen, Y.C. Cohen, J. Hillengass, S. Anguille, T. Kerre, W. Roeloffzen, J.M. Schechter, K.C. De Braganca, H. Varsos, L. Wang, M. Vogel, E. Zudaire, C. Corsale, M. Akram, D. Geng, T. Nesheiwat, L. Pacaud, P. Sonneveld, S. Zweegman (Amsterdam-NL, Leuven-BE, Pittsburgh-USA, Philadelphia-USA, Tel Aviv-IL, Buffalo-USA, Edegem-BE, Ghent-BE, Groningen-NL, Raritan -USA, Spring House-USA, Piscataway-USA, Rotterdam-NL)

**B08**

A THIRD BNT162B2 DOSE INDUCES ANTIBODY RESPONSES AGAINST SARS-COV-2 EVEN IN PREVIOUSLY NON-RESPONDERS WITH MULTIPLE MYELOMA

E. Terpos, M. Gavriatopoulou, I. Ntanasis-Stathopoulos, A. Briasoulis, S.Gumeni, P. Malandrakis, E.D. Papanagnou, M. Migkou, N. Kanellias, E. Kastritis, I.P. Trougamos, M.A. Dimopoulos (Athens-GR)

## THURSDAY, APRIL 7, 2022

### 13.40-14.10 **SESSION V: BIOLOGY**

*Chairpersons: N.C. Munshi, N. Raje*

Genetic evolution:

- From benign to malignant disease - **N. Bolli**
- Stromal and immune micro-environment - **T. Cupedo**
- Druggable MM therapeutics: Pathogenetic pathways - **E.M. Ocio**

### 14.20-15.50 **JANSSEN SPONSORED SYMPOSIUM**

#### **Considerations for treatment sequencing in multiple myeloma: a roadmap to cure**

Welcome and introduction - **S. Zweegman**

Current treatment strategies in patients with multiple myeloma - **P. Moreau**

Patient case discussion:

- Planning the patient journey for a transplant eligible patient with MM from front-line to fourth-line therapy - **S. Zweegman**
- Discussion
- Considerations for a transplant ineligible patient regarding treatment sequencing from front-line to fourth-line of therapy in multiple myeloma - **R. Mina**
- Discussion

### 16.00-16.50 **SESSION VI: HOW TO DEFINE HIGH-RISK MYELOMA ACCORDING TO NEW PROGNOSTIC FACTORS**

*Chairpersons: J. San Miguel, P. Sonneveld*

Cytogenetic risk factors: is it time for revision? Detection and impact of 1q & R2-ISS - **M. D'Agostino**

Emergence of high-risk clones - **H. Avet-Loiseau**

Circulating tumor cells - **B. Paiva**

Extramedullary disease - **M. Beksac**

Early relapse - **K. Yong**

### 17.00-18.30 **BRISTOL MEYERS SQUIBB SPONSORED SYMPOSIUM**

#### **Novel immunotherapies for advancing the treatment of multiple myeloma**

Welcome and introduction - **T. Facon**

Evolving standard of care in NDMM and RRMM - **T. Facon**

Cellular therapies: a new era of treatment in MM - **M.V. Mateos**

Emerging immune therapies for RRMM: targets and modalities - **P. Rodriguez-Otero**

Emerging preclinical and clinical data for iberdomide and CC-92480 - **N. van de Donk**

Discussion

### 18.40-19.20 **SESSION VII: MRD IN MM**

*Chairpersons: G. Jackson, B. Paiva*

MRD in the bone marrow - **S. Oliva**

MRD in the peripheral blood: mass spec - **N. Puig**

MRD outside of the bone marrow: imaging - **E. Zamagni**

## FRIDAY, APRIL 8, 2022

### 13.40- 14.40 **SESSION VIII: NEWLY DIAGNOSED MM**

*Chairpersons:* R. Hajek, X. Leleu

Transplant-eligible:

- Which induction therapy: where to aim for and when to switch - **P. Moreau**
- Upfront ASCT: does one size fits all? - **M. Cavo**
- Consolidation and maintenance - **P. Sonneveld**
- How to treat high risk patients - **M. Kaiser**

Non-Transplant-eligible:

- How to treat fit patients - **T. Facon**
- How to treat unfit and frail patients - **G. Cook**

### 14.50-16.20 **GSK SPONSORED SYMPOSIUM**

#### **Future treatment and management of heavily pre-treated and refractory MM patients**

Opening remarks: **M.V. Mateos**

Future combinations in heavily pre-treated and refractory MM patients - **E. Zamagni**

Improving patient's outcome through adverse events management

Focus on: Early recognition and management of corneal toxicity - **M. Labetoulle**

Focus on: Managing neurotoxicity - **J. Gallego**

Focus on: MM management in the context of COVID - **M. Von Lilienfeld-Toal**

Closing remarks - **M.V. Mateos**

### 16.30-17.00 **SESSION IX: TREATMENT AT RELAPSE**

*Chairpersons:* M. Boccadoro, M.A. Dimopoulos

What to do first - **M.V. Mateos**

How to sequence after first relapse - **C. Pawlyn**

How to treat triple class refractory myeloma - **P. Rodriguez-Otero**

### 17.10-18.40 **SANOFI SPONSORED SYMPOSIUM**

#### **Climb every mountain: New routes to tackle in RRMM**

*Chairperson:* **A. Broijl**

Introduction: State of the art treatment of high-risk patients in RRMM - **A. Broijl**

Finding the right path: Exploring the nuances of high-risk cytogenetics - **A. Broijl**

A challenging ascent: The impact of renal impairment - **M. Raab**

New peaks to explore: Considerations for frail and elderly patients - **S. Manier**

A changing view? The role of EMD in patients with RRMM - **E. Zamagni**

Discussion

### 18.50-19.20 **SESSION X: IMMUNETHERAPIES IN MM**

*Chairpersons:* **H. Einsele, C. Fernández de Larrea**

CAR-T cell therapies - **N. Raje**

Bispecific antibodies - **N. van de Donk**

How to choose & sequence immunotherapy - **N.C. Munshi**

## SATURDAY, APRIL 9, 2022

- 9.00-9.30 **SESSION XI: AL AMYLOIDOSIS**  
*Chairpersons: M.C. Minnema, G. Palladini*  
Disease mechanisms & biomarkers - **G. Palladini**  
Early diagnosis and optimal treatment - **E. Kastiris**  
Light chain deposition disease - **J.M.I. Vos**
- 9.40-10.00 **SESSION XII: WHAT KIND OF TRIALS DO WE NEED IN THE FUTURE?**  
*Chairpersons: R. Mina, K.C. Weisel*  
Immunotherapy - **H. Einsele**  
Elderly patients - **S. Zweegman**
- 10.15-10.45 **ADAPTIVE SPONSORED LECTURE**  
*Chairpersons: R. Mina, K.C. Weisel*  
Assessing Measurable Residual Disease in Multiple Myeloma patients  
in Routine Clinical Practice - **K. Ramasamy**
- 11.00-11.30 **SESSION XIII: SIDE EFFECTS MANAGEMENT**  
*Chairpersons: J. Radocha, L. Rasche*  
Prophylaxis - **M. Delforge**  
Covid-19 and myeloma - **H. Ludwig**  
Bone disease - **E. Terpos**
- 11.30-11.45 **CONCLUSIONS AND FINAL GREETINGS**

## POSTER

### 1. BIOLOGY AND PRECLINICAL

#### P01

ARGININE STARVATION IN MULTIPLE MYELOMA MICROENVIRONMENT CONVEYS BORTEZOMIB REFRACTORINESS VIA TLR4 PATHWAY

A. Romano, G. Scandura, C. Giallongo, E. La Spina, A. Barbato, D. Tibullo, F. Di Raimondo (Catania)

### 2. NEWLY DIAGNOSED MULTIPLE MYELOMA

#### P02

PROGNOSTIC STRATIFICATION OF STANDARD RISK MULTIPLE MYELOMA DEFINED BY REVISED ISS

G. Barilà, L. Bonaldi, A. Martines, A. Pascarella, S. Vedovato, C. Clissa, N. Macrì, A. Bonalumi, L. Pavan, M. Tinelli, S. Nalio, A. Teramo, G. Calabretto, V.R. Gasparini, M. Krampera, R. Bassan, R. Zambello (Venezia, Padova-IT)

#### P03

RATIONALE AND DEVELOPMENT OF AN E-HEALTH APPLICATION TO DELIVER PATIENT CENTERED CARE DURING TREATMENT FOR MULTIPLE MYELOMA IN THE NETHERLANDS

P. Geerts, J. Eijsink, A. Moser, P. ter Horst, C. Boersma, M. Postma (Zwolle-NL, Maastricht-NL, Heerlen-NL, Groningen-NL)

### 3. RELAPSED/REFRACTORY MULTIPLE MYELOMA

#### P04

DARATUMUMAB PLUS BORTEZOMIB AND DEXAMETHASONE VERSUS BORTEZOMIB AND DEXAMETHASONE ALONE IN PATIENTS WITH PREVIOUSLY TREATED MULTIPLE MYELOMA: OVERALL SURVIVAL RESULTS FROM THE PHASE 3 CASTOR TRIAL

P. Sonneveld, A. Chanan-Khan, K. Weisel, A.K. Nooka, T. Masszi, M. Beksac, I. Spicka, V. Hungria, M. Munder, M.V. Mateos, T.M. Mark, M.D. Levin, T. Ahmadi, X. Qin, W. Garvin Mayo, X. Gai, J. Carey, R. Carson, A. Spencer (Rotterdam-NL, Jacksonville-FL, Hamburg-DE, Atlanta-GA, Budapest, Hungary-H, Ankara-TR, Prague-CS, São Paulo-BR, Mainz-DE, Salamanca, Spain-E, Aurora-CO, Dordrecht-NL, Plainsboro-NJ, Spring House-PA, Raritan-NJ, Beijing-RC, Melbourne-AUS)

#### P05

DARATUMUMAB PLUS LENALIDOMIDE AND DEXAMETHASONE VERSUS LENALIDOMIDE AND DEXAMETHASONE ALONE IN PATIENTS WITH PREVIOUSLY TREATED MULTIPLE MYELOMA: OVERALL SURVIVAL RESULTS FROM THE PHASE 3 POLLUX TRIAL

M.A. Dimopoulos, A. Oriol, H. Nahi, J. San-Miguel, N.J. Bahlis, S.Z. Usmani, N. Rabin, R.Z. Orłowski, K. Suzuki, T. Plesner, S.S. Yoon, D. Ben Yehuda, P.G. Richardson, H. Goldschmidt, D. Reece, T. Ahmadi, X. Qin, W. Garvin Mayo, X. Gai, J. Carey, R. Carson, P. Moreau (Athens-GR, Barcelona-ES, Stockholm-S, Pamplona-ES, Calgar-AB, New York-USA, London-UK, Houston-TX, Tokyo- J, Vejle-DK, Seoul-ROK, Jerusalem-IL, Boston-MA, Heidelberg-DE, Toronto-CDN, Plainsboro-NJ, Spring House-PA, Raritan-NJ, Beijing-RC, Nantes-FR)



**P06**  
UPDATED RESULTS FROM THE PHASE 1/2 MAJESTEC-1 STUDY OF TECLISTAMAB, A B-CELL MATURATION ANTIGEN X CD3 BISPECIFIC ANTIBODY, IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA

R. Popat, S. Usman, A. Garfall, N. van de Donk, H. Nahi, J. San-Miguel, A. Oriol, A. Nooka, T. Martin, L. Rosinol, A. Chari, L. Karlin, L. Benboubker, M. Mateos, N. Bahlis, P. Moreau, B. Besemer, J. Martínez-López, S. Sidana, L. Pei, D. Trancucci, R. Verona, S. Girgis, Y. Olyslager, M. Jaffe, C. Uhlar, T. Stephenson, R. Van Rampelbergh, A. Banerjee, J. Goldberg, R. Kobos, A. Krishnan (*London-UK, Charlotte-USA, Philadelphia-USA, Amsterdam-NL, Stockholm-SE, Pamplona-ES, Barcelona-ES, Atlanta-USA, San Francisco-USA, New York-USA, Pierre-Bénite-FR, Tours-FR, Salamanca-ES, Calgary-CA, Nantes-FR, Tuebingen-DE, Madrid-ES, Palo Alto-USA, Raritan-USA, Spring House-USA, Antwerp-BE, Duarte-USA*)

**P07**  
RESULTS FROM THE CC-220-MM-001 DOSE-EXPANSION PHASE OF IBERDOMIDE PLUS DEXAMETHASONE IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA  
N.W.C.J. van de Donk, R. Popat, C. Hulin, S. Jagannath, A. Oriol, P.G. Richardson, T. Facon, K. Weisel, J.T. Larsen, M. Minnema, A. Abdallah, A.Z. Badros, S. Knop, E.A. Stadtmauer, M. Chen, T.V. Nguyen, A. Amin, T. Peluso, S. Lonial (*Amsterdam-NL, London-UK, Pessac-FR, New York-USA, Badalona-ES, Boston-MA, Lille-FR, Hamburg-DE, Phoenix-AZ, Utrecht-NL, Kansas City-KS, Baltimore-MD, Würzburg-DE, Philadelphia-PA, Princeton-NJ, Boudry-CH, Atlanta-GA*)

**P08**  
CARTITUDE-2 UPDATE: CILTACABTAGENE AUTOLEUCEL, A B-CELL MATURATION ANTIGEN-DIRECTED CHIMERIC ANTIGEN RECEPTOR T-CELL THERAPY, IN LENALIDOMIDE-REFRACTORY PATIENTS WITH PROGRESSIVE MULTIPLE MYELOMA AFTER 1-3 PRIOR LINES OF THERAPY  
H. Einsele, A.D. Cohen, M. Delforge, J. Hillengass, H. Goldschmidt, K. Weisel, M.-S. Raab, C. Scheid, J.M. Schechter, K.C. De Braganca, H. Varsos, T.-M. Yeh, L. Wang, M. Vogel, C. Corsale, M. Akram, L. Pacaud, T. Nesheiwat, M. Agha, Y.C. Cohen (*Würzburg-DE, Philadelphia-USA, Leuven-BE, Buffalo-USA, Heidelberg-DE, Hamburg-DE, Cologne-DE, Raritan-USA, Piscataway-USA, Pittsburgh-USA, Aviv-IL*)

**P09**  
ATTRITION RATES IN MULTIPLE MYELOMA UNDER REAL WORLD CONDITIONS – AN ANALYSIS FROM THE AUSTRIAN MYELOMA REGISTRY

M.A. Benda, H. Ulmer, R. Weger, T. Winder, B. Hartmann, I. Strassl, S. Sormann, E. Willenbacher, W. Willenbacher (*Feldkirch-DE, Triesen-Liechtenstein-A, Innsbruck-A, Linz-A, Graz-A*)

**P10**  
TALQUETAMAB, A G PROTEIN-COUPLED RECEPTOR FAMILY C GROUP 5 MEMBER D X CD3 BISPECIFIC ANTIBODY, IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM): UPDATED PHASE 1 RESULTS FROM MONUMENTAL-1

N.W.C.J. van de Donk, M.C. Minnema, J.G. Berdeja, A. Oriol, A. Krishnan, P. Rodríguez-Otero, E. Askari, M. Mateos, L.J. Costa, R. Verona, J. Ma, S. Girgis, S. Yang, B. W. Hilder, J. Russell, J.D. Goldberg, A. Chari (*Amsterdam-NL, Utrecht-NL, Nashville-USA, Badalona-ES, Duarte-USA, Navarra-ES, Madrid-ES, Salamanca-ES, Birmingham-USA, Spring House-USA, Raritan-USA, New York-USA*)

**P11**  
IXAZOMIB WITH CYCLOPHOSPHAMIDE AND DEXAMETHASONE IN RELAPSED OR REFRACTORY MYELOMA: MUKEIGHT PHASE II RANDOMISED CONTROLLED TRIAL RESULTS  
H. Auner, S. Brown, K. Walker, J. Kendall, B. Dawkins, D. Meads, G. Morgan, M. Kaiser, M. Cook, S. Roberts, C. Parrish, G. Cook (*London-UK, Leeds-UK, New York-USA, Birmingham-UK*)

**P12**  
TREATMENTS IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA: RETROSPECTIVE CHART REVIEW OF REAL-WORLD OUTCOMES FOR STANDARD OF CARE  
M.-C. Vekemans, M. Delforge, S. Anguille, J. Depaus, N. Meuleman, A. Van de Velde, I. Vande Broek, D. Strens, S. Van Hoorenbeeck, E.J. Moorkens, J. Diels, F. Ghilotti, S. Dalhuisen, S. Vandervennet (*Brussels-BE, Leuven-BE, Antwerp-BE, Edegem-BE, Yvoir-BE, Liege-BE, Sint-Niklaas-BE, Grimbergen-BE, Beerse-BE, Cologno Monzese, Breda-NL*)

**P13**  
CAN PATIENT-REPORTED OCULAR SYMPTOMS GUIDE DOSE MODIFICATIONS IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA RECEIVING BELANTAMAB MAFODOTIN?  
R. Papat, A. Badros, S. Kumar, P. Rodriguez-Otero, A. Cohen, S. Manier, P. Voorhees, F. Gay, R. Rifkin, T. Martin, A. Chari, K. Weisel, A. Farooq, B. Jeng, W. Chng, H. Lee, J. Berdeja, V. Jadhav, A. Tosolini, L. Eliason, A. Palumbo, M. Dimopoulos, S. Lonial, S. Trudel, P. Richardson, E. Terpos (*London-UK, Baltimore-USA, Rochester-USA, NavarraES, Philadelphia-USA, Lille-FR, Charlotte-USA, Torino, Steamboat Springs-USA, San Francisco-USA, New York-USA*), *Hamburg-DE, Chicago-USA, Singapore-J, Houston-USA, Nashville-US, Bengaluru-IND, Upper Providence-USA, Zug-CH, Athens-GR, Atlanta-USA, Toronto-CDN, Boston-USA*)

**P14**  
DREAMM-9: PHASE I STUDY OF BELANTAMAB MAFODOTIN PLUS STANDARD OF CARE IN PATIENTS WITH TRANSPLANT-INELIGIBLE NEWLY DIAGNOSED MULTIPLE MYELOMA  
S. Usmani, A. Alonso, H. Quach, Y. Koh, A. Guenther, CK. Min, X. Leleu, AO. Abdallah, A. Oriol, B. Bessemer, M. Garg, I. Sandhu, K. Weisel, E. Ocio San Miguel, M. Cavo, X. Zhou, M. Kaisermann, L. Mis, D. Williams, A. Yeakey, G. Ferron-Brady, D. Figueroa, B. Kremer, I. Gupta, W. Janowski (*Charlotte-USA, Madrid-ES, Melbourne-AUS, Seoul-ROK, Schwerin-DE, Poitiers-FR, Kansas City-USA, Badalona-ES, Tübingen-DE, Leicester-UK, Edmonton-CDN, Hamburg-DE, Santander-ES, Bologna, Waltham-USA, Upper Providence-USA, Mississauga-CDN, Research Triangle Park-USA, Newcastle-AUS*)

**P15**  
EVOLUTION OF MULTIPLE MYELOMA TREATMENT PATTERNS FROM 2015 THROUGH 2019: REAL-WORLD EVIDENCE FROM A EUROPEAN DATABASE STUDY  
A. Oriol Rocafiguera T.H. Steinmetz, A. Brescianini, S. Gonzalez-McQuire, N. Eugene, A. Abbasi, S. Wetten, X. Leleu (*Badalona-ES, Barcelona-ES, Cologne-DE, Rotkreuz-CH, Uxbridge-UK, Poitiers-FR*)

**P16**  
DARATUMUMAB MONOTHERAPY HAS A FAVORABLE EFFECT ON BONE METABOLISM IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA; RESULTS OF THE PHASE 2 REBUILD STUDY  
E. Terpos, I. Ntanasis-Stathopoulos, E. Kastritis, E. Hatjiharissi, E. Katodritou, E. Eleutherakis-Papaiakovou, E. Verrou, M. Gavriatopoulou, A. Leonidakis, S. Delimpasi, P. Malandrakis, M-C. Kyrtsonis, M. Papaioannou, A. Symeonidis, M.A. Dimopoulos (*Athens-GR, Thessaloniki-GR, Patras-GR*)

**P17**  
DARATUMUMAB (D) PLUS LENALIDOMIDE (R) AND DEXAMETHASONE (D) AS SALVAGE THERAPY FOR PATIENTS WITH REFRACTORY-RELAPSED MULTIPLE MYELOMA (RRMM): INITIAL FOLLOW-UP OF AN ITALIAN MULTICENTER RETROSPECTIVE CLINICAL EXPERIENCE BY “RETE EMATOLOGICA PUGLIESE”  
G. Mele, N. Cascavilla, N. Di Renzo, A. Guarini, P. Mazza L. Melillo, V. Pavone, G. Tarantini, P. Curci, A.P. Falcone, C. Germano, A. Mele, G. Palazzo, G. Palumbo, G. Reddiconto, B. Rossini, G. Specchia, P. Musto, D. Pastore (*Brindisi, San Giovanni Rotondo, Lecce, Bari, Taranto, Foggia, Tricase, Barletta*)

**P18**  
DARATUMUMAB (D) PLUS BORTEZOMIB (V) AND DEXAMETHASONE (D) AS SALVAGE THERAPY FOR PATIENTS WITH REFRACTORY/RELAPSED MULTIPLE MYELOMA (RRMM): INITIAL FOLLOW-UP OF AN ITALIAN MULTICENTER RETROSPECTIVE CLINICAL EXPERIENCE BY “RETE EMATOLOGICA PUGLIESE”  
G. Mele, N. Cascavilla, N. Di Renzo, A. Guarini, P. Mazza, L. Melillo, V. Pavone, G. Tarantini, P. Curci, A.P. Falcone, C. Germano, A. Mele, G. Palazzo, G. Palumbo, G. Reddiconto, B. Rossini, G. Specchia, P. Musto, D. Pastore (*Brindisi, San Giovanni Rotondo, Lecce, Bari, Taranto, Foggia, Tricase, Barletta*)

**P19**  
BASELINE CORRELATES OF COMPLETE RESPONSE TO IDECABTAGENE VICLEUCEL (IDE-CEL, BB2121), A BCMA-DIRECTED CAR T CELL THERAPY IN PATIENTS WITH RELAPSED AND REFRACTORY MULTIPLE MYELOMA: SUBANALYSIS OF THE KARMMMA TRIAL  
P. Rodríguez-Otero, N. Shah, N. Munshi, J. Berdeja, S. Jagannath, O. Finney, N. Martin, A. Agarwal, E. Rowe, T. Campbell, J. San-Miguel (*Pamplona-ES, San Francisco-USA, Boston-USA, Nashville-USA, New York-USA, Cambridge-USA, Princeton-USA*)

**P20**  
POLYCENTRIC “REAL LIFE” STUDY OF BELANTAMAB MAFODOTIN FOR RELAPSED/REFRACTORY MULTIPLE MYELOMA  
R. Iula, F. Trastulli, R. Della Pepa, A. D’Ambrosio, M. Romano, A. Leone, G. Gaeta, S. Palmieri, S. Rocco, F. Pane, F. Ferrara, L. Catalano (*Napoli*)

**P21**  
SUBSEQUENT ANTI-MYELOMA THERAPY AFTER IDECABTAGENE VICLEUCEL (IDE-CEL, BB2121) TREATMENT IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA FROM THE KARMMA STUDY  
P. Rodríguez-Otero, J. San-Miguel, L.D. Anderson Jr, S. Lonial, A. Truppel-Hartmann, J. Sanford, E. Rowe, T.B. Campbell, N. Munshi (*Pamplona-ES, Dallas-USA, Atlanta-USA, Cambridge-USA, Princeton-USA, Boston-USA*)

**P22**  
A NON-INTERVENTIONAL, PROSPECTIVE, OBSERVATIONAL STUDY OF RELAPSED/REFRACTORY MULTIPLE MYELOMA PATIENTS TREATED WITH IXAZOMIB IN REAL-WORLD SETTINGS IN GREECE; INTERIM RESULTS OF THE 'OL-ORAL' STUDY  
E. Katodritou, M.C. Kyrtsonis, S. Delimpasi, E. Spanoudakis, G. Vassilopoulos, P. Zikos, N. Viniou, G. Kaiafa, M. Papathanasiou, V. Pappa, E. Michalis, I. Adamopoulos, K. Kokoviadou, G. Tsirakis, C. Poziopoulos, E. Terpos (*Thessaloniki-GR, Athens-GR, Alexandroupoli-GR, Larissa-GR, Patras-GR, Kalamata-GR, Chania-GR*)

**P23**  
RELAPSED/REFRACTORY MULTIPLE MYELOMA PATIENTS. A MULTICENTER RETROSPECTIVE ANALYSIS OF ELIGIBILITY CRITERIA FOR CAR-T CELL THERAPY  
F. Fazio, A. Di Rocco, T. Za, V. Tomarchio, A. Rago, A. Piciocchi, T. Caravita di Toritto, O. Annibali, V. De Stefano, R. Foà, M. Martelli, M.T. Petrucci (*Roma*)

**P24**  
EXPERT PERSPECTIVES OF UNMET NEED IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM) WHO RECEIVE LENALIDOMIDE-SPARING REGIMENS IN EUROPE  
M. Mateos, X. Leleu, E. Zamagni, M. Delforge, S. Bringhen, A. Broijl, J. de la Rubia, A. Shaw, A. Brescianini, S. Gonzalez-McQuire, S. Patel, P. Moreau (*Salamanca-ES, Poitiers-FR, Bologna, Leuven-BE, Torino, Rotterdam-NL, Valencia-ES, Oxford-UK, Rotkreuz-CH, Uxbridge-UK, Nantes-FR*)

#### 4. SPECIAL CONDITIONS

**P25**  
CARFILZOMIB-BASED TREATMENTS COULD BE ADDED TO IMPEDE-VTE SCORE TO BETTER PREDICT VENOUS THROMBOEMBOLIC RISK IN MM PATIENTS  
S. Morè, V.M. Manieri, L. Corvatta, E. Morsia, S. Rupoli, A. Olivieri, M. Offidani (*Ancona, Fabriano*)

**P26**  
EXTRAMEDULLARY MULTIPLE MYELOMA: A MONOCENTRIC RETROSPECTIVE OBSERVATIONAL STUDY  
M. Brescini, F. Fazio, M.T. Petrucci (*Roma*)

**P27**  
HUMORAL RESPONSE RATE POST MRNA COVID19 VACCINATION (BNT162B2) IS HIGHLY DEPENDENT TO BONE MARROW PLASMACYTOSIS: LONG FOLLOW-UP OF SYMPTOMATIC MULTIPLE MYELOMA PATIENTS  
G. Mele, C. Romano, A. Spina, F. Merchionne, G. Quintana, M. Urbano, A.M. Pasanisi, E. Rinaldi, M.P. Solfrizzi, A. Romano, G. Guaragna, M.L. DiNoi, A. Miccoli, A. Santoro, D. Pastore (*Brindisi*)

**P28**  
RESPONSE AND VACCINATION STATUS OR LACK OF IMMUNOPARESIS ARE ASSOCIATED WITH BETTER OUTCOME FOLLOWING COVID-19 INFECTION AMONG PATIENTS DIAGNOSED WITH MULTIPLE MYELOMA: A SINGLE CENTER EXPERIENCE ON 110 PATIENTS  
G. Cengiz Seval, E. Kircali, D. Koyun, B. Karakaya, H. Yilmaz, G. Yavuz, H. Akbulut, S.K. Toprak, P. Topcuoglu, O. Arslan, M. Ozcan, O. Ilhan, M. Beksac (*Ankara-TR*)

**P29**  
EFFECTS OF VACCINATION ON INCIDENCE AND OUTCOME OF SARS-COV-2 INFECTION IN PATIENTS WITH MONOCLONAL GAMMOPATHY OF UNDETERMINED SIGNIFICANCE (MGUS)  
N. Sgherza, R. Rizzi, P. Curci, D. Roccotelli, M. Croce, M. Avantaggiato, L. Ruga, P. Musto (*Bari*)

## PLATINUM SPONSORS



## GOLD SPONSORS



## SILVER SPONSORS



## BRONZE SPONSORS

